143 related articles for article (PubMed ID: 38626072)
1. Could the mitotic count improve personalized prognosis in melanoma patients?
Buja A; Rugge M; Cozzolino C; Dossi F; Zorzi M; Vecchiato A; de Luca G; Del Fiore P; Tropea S; dall'Olmo L; Rossi CR; Boccuzzo G; Mocellin S
PLoS One; 2024; 19(4):e0302309. PubMed ID: 38626072
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
Patuzzo R; Mattavelli I; Gallino G; Galeone C; Valeri B; Mocellin S; Del Fiore P; Ribero S; Mandalà M; Tauceri F; Lombardo M; Maurichi A;
Cancer; 2023 Aug; 129(15):2331-2340. PubMed ID: 37162404
[TBL] [Abstract][Full Text] [Related]
3. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
4. Mitotic rate as an important prognostic factor in cutaneous malignant melanoma.
Piñero-Madrona A; Ruiz-Merino G; Cerezuela Fuentes P; Martínez-Barba E; Rodríguez-López JN; Cabezas-Herrera J
Clin Transl Oncol; 2019 Oct; 21(10):1348-1356. PubMed ID: 30783917
[TBL] [Abstract][Full Text] [Related]
5. Is mitotic rate still useful in the management of patients with thin melanoma?
Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
Thompson JF; Soong SJ; Balch CM; Gershenwald JE; Ding S; Coit DG; Flaherty KT; Gimotty PA; Johnson T; Johnson MM; Leong SP; Ross MI; Byrd DR; Cascinelli N; Cochran AJ; Eggermont AM; McMasters KM; Mihm MC; Morton DL; Sondak VK
J Clin Oncol; 2011 Jun; 29(16):2199-205. PubMed ID: 21519009
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
8. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study.
Ipenburg NA; Lo SN; Vilain RE; Holtkamp LHJ; Wilmott JS; Nieweg OE; Thompson JF; Scolyer RA
J Am Acad Dermatol; 2020 Apr; 82(4):910-919. PubMed ID: 31682859
[TBL] [Abstract][Full Text] [Related]
10. Predictors of sentinel lymph node status in cutaneous melanoma: a classification and regression tree analysis.
Tejera-Vaquerizo A; Martín-Cuevas P; Gallego E; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
Actas Dermosifiliogr; 2015 Apr; 106(3):208-18. PubMed ID: 25616352
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
[TBL] [Abstract][Full Text] [Related]
12. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 May; 51(6):873-878. PubMed ID: 33758939
[TBL] [Abstract][Full Text] [Related]
13. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
14. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
[TBL] [Abstract][Full Text] [Related]
15. Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma.
Tas F; Erturk K
Int J Dermatol; 2022 Apr; 61(4):472-479. PubMed ID: 34633070
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
17. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
Mandalà M; Galli F; Cattaneo L; Merelli B; Rulli E; Ribero S; Quaglino P; De Giorgi V; Pigozzo J; Sileni VC; Chirco A; Ferrucci PF; Occelli M; Imberti G; Piazzalunga D; Massi D; Tondini C; Queirolo P;
J Am Acad Dermatol; 2017 Feb; 76(2):264-273.e2. PubMed ID: 27847125
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity.
Mahiques Santos L; Oliver Martinez V; Alegre de Miquel V
Actas Dermosifiliogr; 2014; 105(1):60-8. PubMed ID: 24021663
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system.
Kashani-Sabet M; Miller JR; Lo S; Nosrati M; Stretch JR; Shannon KF; Spillane AJ; Saw RPM; Cleaver JE; Kim KB; Leong SP; Thompson JF; Scolyer RA
Cancer; 2020 Nov; 126(21):4717-4725. PubMed ID: 32780467
[TBL] [Abstract][Full Text] [Related]
20. Mitotic rate in melanoma: a reexamination.
Attis MG; Vollmer RT
Am J Clin Pathol; 2007 Mar; 127(3):380-4. PubMed ID: 17276944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
